Skip to main content
GutCited

Omega-3 Fatty Acids (EPA/DHA) için Crohn's Disease

C

EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Sonuç

EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.

Key Study Findings

Other
Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. …
Dose: 50, 100, and 200 mg/kg oral vs: Dexamethasone 2.4 mg/kg; DNBS colitis model vs healthy Outcome: Colonic inflammation markers (MPO, NO, MDA, CAT, GSH) Etki: None None

Popülasyon: DNBS-induced Crohn's disease BALB/c mouse model

Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None vs: None Outcome: IBD microbiota modulation and immune regulation Etki: None None

Popülasyon: IBD patients (review of nutritional interventions)

Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None vs: None Outcome: Athletic performance and nutritional optimization Etki: None None

Popülasyon: Vegan athletes (narrative review)

Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None vs: None Outcome: Diet-genetics interaction in IBD Etki: None None

Popülasyon: IBD patients (editorial commentary)

Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None vs: None Outcome: Colitis severity Etki: None None

Popülasyon: Crohn's disease patients

Observational Study
Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: …
Dose: 95% vs: None Outcome: inflammation markers Etki: None None

Popülasyon: None

Key Statistics

6

Çalışmalar

800

Katılımcılar

Mixed

C

Derece

Referenced Papers

Gastroenterology clinics of … 2018 67 atıf
Clinics in dermatology 2016 19 atıf
The Cochrane database … 2014 88 atıf
Alimentary pharmacology & … 2013 128 atıf
The British journal … 2012 145 atıf
The Cochrane database … 2012 130 atıf
The Cochrane database … 2009 198 atıf
Gastroenterology nursing : … 2006 24 atıf
Current opinion in … 2005 22 atıf
Journal of the … 2002 2016 atıf
Current opinion in … 2002 1 atıf
Current opinion in … 2002
Zeitschrift fur Gastroenterologie 1998 18 atıf
Arquivos de gastroenterologia 1996

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:
1,000-2,000 mg combined EPA/DHA per day
ibdsupport:
2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)

Üst sınır: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
50, 100, and 200 mg/kg oral -- Positive --
None -- Positive --
None -- Positive --
None -- Neutral --
None -- Neutral --
95% -- Mixed --
None -- Mixed 12194
None -- Mixed --

En iyi alım zamanı: With meals containing fat for better absorption

Safety & Side Effects

Bildirilen Yan Etkiler

  • Fishy aftertaste and burping
  • Mild gastrointestinal discomfort (nausea, diarrhea)
  • Potential increased bleeding time at very high doses (>3 g/day)
  • May lower blood pressure slightly

Bilinen Etkileşimler

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)
  • Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)

Tolere edilebilir üst alım: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Omega-3 Fatty Acids (EPA/DHA) help with Crohn's Disease?
Based on 6 studies with 800 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 800 total participants. The overall direction of effect is mixed.

Related Evidence

Şu durum için diğer içerikler: Crohn's Disease

Omega-3 Fatty Acids (EPA/DHA) diğer sağlık durumları için

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.